References
- Lundin J, Hagberg H, Repp R, Cavallin-Stahl E, Freden S, Juliusson G, et al. Phase II study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003; 101: 4267–72
- Thursky KA, Worth LJ, Seymour JF, Miles Prince H, Slavin MA. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 2006; 132: 3–12
- Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis 2006; 43: 16–24
- Karlsson C, Norin S, Kimby E, Sander B, Porwit Macdonald A, Nilsson B, et al. Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukaemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation. Leukemia 2006; 20: 2204–7
- Fiegl M, Falkner A, Hopfinger G, Brugger S, Zabernigg A, Bauer F, et al. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukaemia: a nation-wide retrospective study in Austria. Cancer 2006; 107: 2408–16
- Peleg AY, Husain S, Kwak EJ, Silveira FP, Ndirangu M, Tran J, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD52 antibody. Clin Infect Dis 2007; 44: 204–12
- Ghobrial IM, Otteman LA, White WL. An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab. N Engl J Med 2003; 349: 2570–2
- O'Brien SM, Kantarjian HM, Thomas DA, Cortes J, Giles FJ, Wierda WG, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukaemia. Cancer 2003; 98: 2657–63
- O'Brien SM, Keating MJ, Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukaemia treated with alemtuzumab. Clin Lymphoma Myeloma 2006; 7: 125–30
- Janssens A, Berth M, De Paepe P, Verhasselt B, Van Roy N, Noens L, et al. EBV negative Richter's syndrome from a coexistent clone after salvage treatment with alemtuzumab in a CLL patient. Am J Hematol 2006; 81: 706–12
- Cavalli-Bjorkman N, Osby E, Lundin J, Kalin M, Osterborg A, Gruber A. Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukaemia. Med Oncol 2002; 19: 277–80
- Myers GD, Krance RA, Weiss H, Kuehnle I, Demmler G, Heslop HE, et al. Adenovirus infection rates in paediatric recipients of alternate donor allogeneic bone marrow transplants receiving either anti-thymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant 2005; 36: 1001–8